Zomedica Corp. ZOM
We take great care to ensure that the data presented and summarized in this overview for Zomedica Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZOM
View all-
Vanguard Group Inc Valley Forge, PA48.3MShares$6.28 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA9.93MShares$1.29 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.86MShares$1.28 Million0.0% of portfolio
-
State Street Corp Boston, MA3.51MShares$456,2840.0% of portfolio
-
Brown Brothers Harriman & CO New York, NY2.47MShares$320,6490.0% of portfolio
-
Northern Trust Corp Chicago, IL1.8MShares$233,7270.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA412KShares$53,6030.0% of portfolio
-
Orion Portfolio Solutions, LLC357KShares$46,4290.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC286KShares$37,1760.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA277KShares$36,0370.0% of portfolio
Latest Institutional Activity in ZOM
Top Purchases
Top Sells
About ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Insider Transactions at ZOM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+3.96%
|
$0
$0.12 P/Share
|
|
Nov 11
2024
|
Russell Kevin Klass Vice President of Sales |
BUY
Open market or private purchase
|
Direct |
500,000
+15.49%
|
$0
$0.12 P/Share
|
|
Nov 11
2024
|
Larry C Heaton Ii CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+16.67%
|
$0
$0.12 P/Share
|
|
Nov 08
2024
|
Anthony K Blair COO |
BUY
Open market or private purchase
|
Direct |
150,000
+27.27%
|
$0
$0.12 P/Share
|
|
Sep 05
2024
|
Larry C Heaton Ii CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+20.0%
|
$0
$0.12 P/Share
|
|
Aug 28
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+4.12%
|
$0
$0.13 P/Share
|
|
Aug 20
2024
|
Anthony K Blair COO |
BUY
Open market or private purchase
|
Direct |
100,000
+28.57%
|
$0
$0.14 P/Share
|
|
Jun 12
2024
|
Russell Kevin Klass Vice President of Sales |
BUY
Open market or private purchase
|
Direct |
299,993
+13.04%
|
$0
$0.16 P/Share
|
|
Jun 11
2024
|
Russell Kevin Klass Vice President of Sales |
BUY
Open market or private purchase
|
Direct |
500,000
+22.73%
|
$0
$0.15 P/Share
|
|
Jun 10
2024
|
Russell Kevin Klass Vice President of Sales |
BUY
Open market or private purchase
|
Direct |
200,007
+14.29%
|
$0
$0.15 P/Share
|
|
Jun 10
2024
|
Peter Donato Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$0
$0.15 P/Share
|
|
May 17
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+2.22%
|
$0
$0.18 P/Share
|
|
May 16
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
25,000
+1.16%
|
$0
$0.18 P/Share
|
|
May 14
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
50,000
+1.18%
|
$0
$0.14 P/Share
|
|
May 13
2024
|
Anthony K Blair COO |
BUY
Open market or private purchase
|
Direct |
150,000
+50.0%
|
$0
$0.14 P/Share
|
|
May 13
2024
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+4.65%
|
$0
$0.14 P/Share
|
|
May 13
2024
|
Larry C Heaton Ii CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+25.0%
|
$0
$0.14 P/Share
|
|
Dec 15
2023
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+98.09%
|
$0
$0.16 P/Share
|
|
Nov 17
2023
|
Johnny D Powers |
BUY
Open market or private purchase
|
Direct |
100,000
+5.13%
|
$0
$0.17 P/Share
|
|
Nov 17
2023
|
Larry C Heaton Ii CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+33.33%
|
$0
$0.17 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 2.7M shares |
|---|